<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Metab Brain Dis</journal-id><journal-id journal-id-type="iso-abbrev">Metab Brain Dis</journal-id><journal-title-group><journal-title>Metabolic Brain Disease</journal-title></journal-title-group><issn pub-type="ppub">0885-7490</issn><issn pub-type="epub">1573-7365</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39656322</article-id><article-id pub-id-type="pmc">PMC11632008</article-id>
<article-id pub-id-type="publisher-id">1436</article-id><article-id pub-id-type="doi">10.1007/s11011-024-01436-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Value of systemic inflammation markers for the detection of minimal and prediction of overt hepatic encephalopathy after TIPS insertion</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tiede</surname><given-names>Anja</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stockhoff</surname><given-names>Lena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ehrenbauer</surname><given-names>Alena F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rieland</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cornberg</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Meyer</surname><given-names>Bernhard C.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gabriel</surname><given-names>Maria M.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Wedemeyer</surname><given-names>Heiner</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hinrichs</surname><given-names>Jan B.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Weissenborn</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Falk</surname><given-names>Christine S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Maasoumy</surname><given-names>Benjamin</given-names></name><address><email>Maasoumy.benjamin@mh-hannover.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f2yqf98</institution-id><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution-id institution-id-type="ISNI">0000 0000 9529 9877</institution-id><institution>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, </institution><institution>Hannover Medical School, </institution></institution-wrap>Hannover, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/028s4q594</institution-id><institution-id institution-id-type="GRID">grid.452463.2</institution-id><institution>German Center for Infection Research (DZIF), </institution></institution-wrap>Hannover-Braunschweig, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04s99xz91</institution-id><institution-id institution-id-type="GRID">grid.512472.7</institution-id><institution>Center for Individualized Infection Medicine (CIIM), </institution></institution-wrap>c/o CRC Hannover, Hannover, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f2yqf98</institution-id><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution-id institution-id-type="ISNI">0000 0000 9529 9877</institution-id><institution>Department of Diagnostic and Interventional Radiology, </institution><institution>Hannover Medical School, </institution></institution-wrap>Hannover, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01t4pxk43</institution-id><institution-id institution-id-type="GRID">grid.460019.a</institution-id><institution>St. Bernward Hospital, </institution></institution-wrap>Radiology, Hildesheim, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f2yqf98</institution-id><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution-id institution-id-type="ISNI">0000 0000 9529 9877</institution-id><institution>Department of Neurology, </institution><institution>Hannover Medical School, </institution></institution-wrap>Hannover, Germany </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f2yqf98</institution-id><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution-id institution-id-type="ISNI">0000 0000 9529 9877</institution-id><institution>Institute of Transplant Immunology, </institution><institution>Hannover Medical School, </institution></institution-wrap>Hannover, Germany </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>40</volume><issue>1</issue><elocation-id>58</elocation-id><history><date date-type="received"><day>9</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Development of overt hepatic encephalopathy (oHE) is a particularly feared complication when considering treatment with transjugular intrahepatic portosystemic shunt (TIPS). However, the pathophysiology of HE, in particular after TIPS-insertion, is complex and valid predictors remain scarce. We aimed to investigate whether systemic inflammation markers (SIM) are linked to minimal (mHE) and overt HE (oHE) development before and after TIPS. 62 prospectively recruited patients undergoing TIPS-insertion were included and monitored for oHE occurrence two years thereafter. Patients underwent psychometric testing including the portosystemic encephalopathy syndrome test (PSE), yielding the psychometric hepatic encephalopathy score (PHES), and Animal Naming Test (ANT) before TIPS (baseline) and during structured follow-up 1, 3, 6 and 12 months afterwards. SIM (IL-6, TNF-&#x003b1; and IL-1&#x003b2;) were measured at corresponding timepoints. Patients were predominantly male (64.5%) with a median age of 58 years and MELD of 11. The majority (75.8%) received a TIPS for treatment of refractory ascites. 67.9% presented with mHE before TIPS. No link between the investigated SIM and PHES or ANT at baseline or during any follow-up was documented. 19 (30.6%) patients developed oHE during follow-up. Neither baseline SIM levels nor test results were significantly associated with risk for oHE. We demonstrated a significant decline of all SIM during follow-up, which did not translate to an ameliorated risk for oHE. In patients undergoing TIPS-insertion, the selected SIM have neither a strong link to post-TIPS-oHE development nor to subclinical changes in psychometric tests for mHE.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11011-024-01436-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>TIPS (Transjugular Intrahepatic Portosystemic Shunt)</kwd><kwd>Systemic Inflammation</kwd><kwd>mHE (Minimal Hepatic Encephalopathy)</kwd><kwd>PHES (Psychometric Hepatic Encephalopathy Score)</kwd></kwd-group><funding-group><award-group><funding-source><institution>Medizinische Hochschule Hannover (MHH) (3118)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par23">In the natural history of liver cirrhosis, the onset and progression of portal hypertension is widely considered the main driver of cirrhosis-related complications (D&#x02019;Amico <xref ref-type="bibr" rid="CR8">2006</xref>; de Franchis et al. <xref ref-type="bibr" rid="CR10">2022</xref>). The prognosis of patients markedly decreases after developing a decompensating event, most commonly ascites or variceal bleeding (European Association for the Study of the Liver&#x000a0;<xref ref-type="bibr" rid="CR15">2018</xref>; D&#x02019;Amico et al. <xref ref-type="bibr" rid="CR9">2018</xref>; de Franchis et al. <xref ref-type="bibr" rid="CR10">2022</xref>). An established causal treatment for these portal hypertension related complications is the insertion of a transjugular intrahepatic portosystemic shunt (TIPS). While TIPS has been shown to decrease the risk for hepatic decompensation, including variceal bleeding and ascites (Larrue et al. <xref ref-type="bibr" rid="CR23">2023</xref>), other complications can arise. One of the most frequent complications after TIPS is the onset of overt hepatic encephalopathy (oHE), occurring in 35&#x02013;50% of patients (European Association for the Study of the Liver <xref ref-type="bibr" rid="CR16">2022</xref>; Ehrenbauer et al. <xref ref-type="bibr" rid="CR13">2023</xref>). While the occurrence of HE after TIPS has not been linked to an increased mortality (Nardelli et al. <xref ref-type="bibr" rid="CR29">2024</xref>), even mild cognitive impairment is associated with a reduced quality of life and higher need for hospitalization (Agrawal et al. <xref ref-type="bibr" rid="CR1">2015</xref>; Ampuero et al. <xref ref-type="bibr" rid="CR3">2018</xref>; Flud and Duarte-Rojo <xref ref-type="bibr" rid="CR17">2019</xref>). As a result, oHE is one of the main reasons for TIPS diameter reduction and occlusion (Gairing et al. <xref ref-type="bibr" rid="CR19">2022b</xref>; Pereira et al. <xref ref-type="bibr" rid="CR30">2016</xref>; Schindler et al. <xref ref-type="bibr" rid="CR34">2020</xref>). Thus, a cautious selection of patients, in particular with regard to the risk for HE, is widely considered to be of high importance (European Association for the Study of the Liver <xref ref-type="bibr" rid="CR16">2022</xref>). Well-established risk factors for post-TIPS oHE include impaired liver function, a history of oHE, and advanced age (Gairing et al. <xref ref-type="bibr" rid="CR19">2022b</xref>). Additionally, a larger stent diameter and portal pressure gradient (PPG) reduction as well as sarcopenia have been found to be associated with a greater risk for post-TIPS oHE (Gairing et al. <xref ref-type="bibr" rid="CR19">2022b</xref>). Unfortunately, valid predictive factors remain scarce.</p><p id="Par24">Some studies suggested that the presence of minimal HE (mHE) may serve as a valid predictive marker, while other studies only found numerical differences (Berlioux et al. <xref ref-type="bibr" rid="CR5">2014</xref>; Ehrenbauer et al. <xref ref-type="bibr" rid="CR13">2023</xref>; Nardelli et al. <xref ref-type="bibr" rid="CR28">2016</xref>; Senzolo et al. <xref ref-type="bibr" rid="CR36">2019</xref>). However, precise assessment of mHE is time consuming, requires trained personnel, even demands expensive special equipment depending on diagnostic test employed (Gairing et al. <xref ref-type="bibr" rid="CR19">2022b</xref>), and may therefore not be suitable to monitor cognitive function after TIPS in routine clinical care. Moreover, the pathological mechanism of HE in general is considered multifactorial in nature, with infections, bleeding and hyperammonaemia being several triggers for its onset (Rose et al. <xref ref-type="bibr" rid="CR33">2020</xref>). TIPS insertion adds to the complexity with a sudden increase of portosystemic shunt volume, which by itself is a well-known risk factor for HE (Praktiknjo et al. <xref ref-type="bibr" rid="CR31">2020</xref>; Sim&#x000f3;n-Talero et al. <xref ref-type="bibr" rid="CR40">2018</xref>). Via the new shunt, the ammonia-rich blood from the gut bypasses the liver parenchyma, effectively circumventing the urea cycle, resulting in further impaired ammonia elimination (Gairing et al. <xref ref-type="bibr" rid="CR19">2022b</xref>). However, this effect may partly be balanced by the benefits of portal pressure reduction including vastly reduced rates of portal hypertensive bleeding, hyponatremia, ascites as well as a mitigation of sarcopenia (Garc&#x000ed;a-Pag&#x000e1;n et al. <xref ref-type="bibr" rid="CR20">2020</xref>; Larrue et al. <xref ref-type="bibr" rid="CR23">2023</xref>; Tsien et al. <xref ref-type="bibr" rid="CR42">2013</xref>).</p><p id="Par25">An important and so far still incompletely studied component of HE development is systemic inflammation (SI), which is nowadays considered a main driver of disease progression in advanced cirrhosis (Arroyo et al. <xref ref-type="bibr" rid="CR4">2021</xref>; Costa et al. <xref ref-type="bibr" rid="CR7">2021</xref>; Engelmann et al. <xref ref-type="bibr" rid="CR14">2021</xref>). Recent studies documented a synergistic mechanism of SI in the development of oHE. Several systemic inflammatory markers (SIM), including TNF-&#x003b1; and IL-1&#x003b2;, have been associated with blood brain barrier dysfunction and consecutively increased sensitivity to ammonium (Aldridge et al. <xref ref-type="bibr" rid="CR2">2015</xref>; de Vires et al. <xref ref-type="bibr" rid="CR11">1996</xref>). Some SIM, most prominently IL-6, have been directly linked to impaired cognitive function (Gairing et al. <xref ref-type="bibr" rid="CR18">2022a</xref>). Thus, some authors suggested a promising role for SIM in the diagnosis of mHE and the prediction of oHE (Gairing et al. <xref ref-type="bibr" rid="CR18">2022a</xref>; Li et al. <xref ref-type="bibr" rid="CR25">2023</xref>). However, the relevance and predictive value of SIM for HE in TIPS patients remain vastly unknown. Hence, this study aims to investigate the link between SIM and the presence of mHE as well as the development of oHE after TIPS insertion.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par26">A number of 109 prospectively recruited patients undergoing TIPS-insertion at Hannover Medical School between 08/2019 and 02/2022 were considered for this study. As part of the patients&#x02019; enrollment in the prospective Hannover TIPS patient registry (Clinical Trials.gov number NCT04801290), patients underwent blood sampling from the cubital vein in addition to psychometric testing both before TIPS (at baseline) and during structured follow-up (FU) at 1, 3, 6 and 12 months after TIPS-insertion.</p><p id="Par27">Patients without liver cirrhosis and those with history of transplantation, permanent hemodialysis and neurological diseases were excluded, as were patients without psychometric tests or measurement of SIM at baseline. Finally, 62 patients were eligible for analysis of SI and oHE development after TIPS (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Patient selection and exclusion criteria</p></caption><graphic xlink:href="11011_2024_1436_Fig1_HTML" id="d33e548"/></fig></p><sec id="Sec3"><title>Data assessment and psychometric testing</title><p id="Par28">Patients were prospectively followed up for death, liver transplantation, as well as oHE development within two years after TIPS insertion. Medication for HE prophylaxis was evaluated at time of psychometric testing before and at discharge after TIPS insertion. Diagnosis for oHE (grade&#x02009;&#x02265;&#x02009;2) was based on the West Haven Criteria and ISHEN (International Society for Hepatic Encephalopathy and Nitrogen Metabolism) criteria (Weissenborn <xref ref-type="bibr" rid="CR44">2019</xref>). Psychometric testing was performed before TIPS as well as at FU1, FU3, FU6 and FU12. It included the PSE syndrome test (version 2.0; 2020) (Schomerus et al. <xref ref-type="bibr" rid="CR35">1999</xref>), yielding the psychometric hepatic encephalopathy score (PHES), and the Animal Naming Test (ANT) (Campagna et al. <xref ref-type="bibr" rid="CR6">2017</xref>). The standardized and validated PSE test is widely regarded as the gold standard and was thus used to diagnose mHE (cut-off: &#x02212;4 points) (Weissenborn <xref ref-type="bibr" rid="CR43">2015</xref>) in our study. For the ANT, we considered 23 animals per minute as the cut-off value for the German population, following Labenz et al. (Labenz and Schattenberg <xref ref-type="bibr" rid="CR21">2018</xref>).</p></sec><sec id="Sec4"><title>TIPS placement</title><p id="Par29">All TIPS implantations were performed by clinically experienced interventional radiologists adhering to the institutional standard operating procedure (Marquardt et al. <xref ref-type="bibr" rid="CR26">2015</xref>; Meine et al. <xref ref-type="bibr" rid="CR27">2020</xref>). Every patient received a polytetrafluoroethylene-covered stent graft (Viatorr<sup>&#x000ae;</sup>, Gore, Flagstaff, Arizona, AZ, USA) with a stent diameter of either 6 (<italic>n</italic>&#x02009;=&#x02009;14), 7 (<italic>n</italic>&#x02009;=&#x02009;1), 8 (<italic>n</italic>&#x02009;=&#x02009;45) or 10&#x000a0;mm (<italic>n</italic>&#x02009;=&#x02009;2) under general anaesthesia.</p></sec><sec id="Sec5"><title>Collection of samples and soluble inflammatory marker assay</title><p id="Par30">Before TIPS insertion and 1, 3, 6 and 12 months thereafter, blood samples (EDTA plasma) were collected from the patient&#x02019;s cubital vein. Immediately after obtaining the plasma samples, trained members of staff centrifuged the samples for 10&#x000a0;min at 3000 rotations per minute followed by storage of the plasma supernatants at &#x02212;80&#x000a0;&#x000b0;C. Utilizing the Luminex based multiplex bead assay (Bio-Plex Pro&#x02122; Human Cytokine Assays, catalog no. 12007283, BioRad Laboratories, Hercules, CA), concentrations of SIM in all available samples from patients included in this study were quantified adhering to the manufacturer&#x02019;s instruction manual. BioPlex Manager&#x02122; software was employed for the acquiring of samples. If concentrations in samples measured below the range of detection, the value was imputed as half the limit of quantification divided by two. All analyzed samples had not previously been thawed and samples obtained during active infection were excluded from all analyses (Suppl. Figure&#x000a0;<xref rid="MOESM1" ref-type="media">9</xref>).</p></sec><sec id="Sec6"><title>Study design</title><p id="Par31">Three different analyses were performed for this study.</p><p id="Par32">
<list list-type="bullet"><list-item><p id="Par33">Analysis 1: Link of selected SIM (IL-6, TNF-&#x003b1; and IL-1&#x003b2;) with psychometric test results (PHES and ANT) before and after TIPS insertion.</p></list-item></list>
</p><p id="Par34">Correlation analyses employing Spearman rho were performed for paired variables (tests and respective SIM) both before TIPS and during follow-up at FU1, FU3, FU6 and FU12. Additionally, levels of SIM were compared between patients with and without mHE at all timepoints using Mann-Whitney U test. Moreover, we analyzed whether the changes of SIM were linked to changes in the psychometric test performances utilizing Chi-squared tests.</p><p id="Par35">
<list list-type="bullet"><list-item><p id="Par36">Analysis 2: Predictive value of baseline SIM for the occurrence of oHE after TIPS insertion during two-year follow-up after TIPS.</p></list-item></list>
</p><p id="Par37">All 62 patients with SIM levels at baseline were monitored for oHE development during two-year follow-up. Competing risk analysis was then employed to investigate the link between baseline SIM as well as mHE test results and post-TIPS oHE. In a multivariable model we adjusted for FIPS (Freiburg index of post-TIPS survival) and known-risk factors of oHE, i.e. stent diameter and history of oHE. As age is included in the FIPS-Score, this factor was not integrated into the multivariable model. In an additional model, we employed albumin instead of the FIPS-Score to avoid multicollinearity.</p><p id="Par38">
<list list-type="bullet"><list-item><p id="Par39">Analysis 3: Predictive value of changes in SIM for the occurrence of oHE during further follow-up.</p></list-item></list>
</p><p id="Par40">A number of 32 patients with available SIM measurements at FU1 were included in this analysis and monitored for occurrence of oHE during further follow-up starting at FU1, ending at two-years after TIPS-insertion. The predictive value of both the absolute changes of SIM-levels from baseline to FU1 as well as binary coded increase vs. decrease of SIM were investigated in univariable competing risk analyses. Similarly, we included 49 patients in a second, late-follow-up analysis, comprising SIM levels from either FU3, FU6 or FU12, and investigated the follow-up period after the available late-FU and oHE-development, employing the aforementioned analysis. Multivariable analyses could not be employed due to low numbers of events in both further follow-up time frames, respectively.</p></sec><sec id="Sec7"><title>Statistics</title><p id="Par41">All statistical analyses were conducted using IBM SPSS Statistics (version 28, SPSS Inc., Chicago, Illinois, USA), GraphPad Prism (GraphPad Software, Version 5) and R Statistical Software (version 4.2.0. with packages &#x0201c;RCmdr&#x0201d; and &#x0201c;rcmr.EZR plug-in&#x0201d;).</p><p id="Par42">Continuous variables are reported as median, if not indicated otherwise, with interquartile range, and categorical variables as numbers and percentages. For comparisons of continuous variables we utilized the Mann-Whitney U test and analogously for categorical variables the Chi-squared or Fisher&#x02019;s exact test. Paired t-test were employed to assess statistical differences between paired variables. Further, correlation between parameters was tested using the Spearman rho test. The predictive value of SIM for oHE development during follow-up was tested using the time-dependent Fine-Gray model for competing risk analysis, treating death and liver transplantation as competing events. In order to evaluate the prognostic value of previously proposed IL-6 cut-offs, we employed Tarone-Ware tests due to crossing survival curves, analogous to log-rank tests in the referenced previous study (Li et al. <xref ref-type="bibr" rid="CR25">2023</xref>). A p-value&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec><sec id="Sec8"><title>Ethics</title><p id="Par43">All patients gave written informed consent to enroll in this prospective study, registered at ClinicalTrials.gov (trial number: NCT04801290). The local ethics committee of Hannover Medical School approved this study (protocol identification number: Nr. 8498_BO_S_2019), which was conducted according to the principles of the Declaration of Helsinki.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Baseline characteristics of patients</title><p id="Par44">Overall, data of 62 patients with liver cirrhosis were analyzed. The majority of patients were male (64.5%) with a median age of 58 years and median MELD- and FIPS-Scores of 11 and &#x02212;&#x02009;0.28, respectively. Most patients (79.0%) were categorized as Child-Pugh B before TIPS-insertion. Alcohol-associated liver disease was the predominant etiology of cirrhosis (51.6%). TIPS-insertion reduced the portal pressure gradient (PPG) from a median of 15mmHg before to a median of 6mmHg, with most common indication being the treatment of refractory ascites (75.8%).</p><p id="Par45">At time of psychometric testing before TIPS-insertion, median PHES was &#x02212;6 (&#x02212;10 - &#x02212;4) and 36 (67.9%) patients presented with mHE as defined by an abnormal PHES. Similarly, the ANT was pathological in 39 (68.4%) patients with a median number of 19 (15&#x02013;24) animals named. At discharge after TIPS-insertion, 82.3% of patients received HE prophylaxis, most commonly Lactulose (77.4%). All baseline characteristics of the study cohort are displayed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Baseline characteristics</th><th align="left">All patients (<italic>n</italic>&#x02009;=&#x02009;62)</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">58.00 [51.25, 65.75]</td></tr><tr><td align="left">Sex female/male (%male)</td><td align="left">22/40 (64.5%)</td></tr><tr><td align="left"><bold>Etiology of cirrhosis</bold>*</td><td align="left"/></tr><tr><td align="left">ALD (%)</td><td align="left">32 (51.6%)</td></tr><tr><td align="left">MetALD (%)</td><td align="left">8 (12.9%)</td></tr><tr><td align="left">MASLD (%)</td><td align="left">6 (9.7%)</td></tr><tr><td align="left">Viral (%)</td><td align="left">4 (6.5%)</td></tr><tr><td align="left">Cryptogenic (%)</td><td align="left">4 (6.5%)</td></tr><tr><td align="left">Other (%)</td><td align="left">10 (16.1%)</td></tr><tr><td align="left"><bold>Indication for TIPS</bold>*</td><td align="left"/></tr><tr><td align="left">Refractory Ascites (%)</td><td align="left">47 (75.8%)</td></tr><tr><td align="left">Variceal bleeding (%)</td><td align="left">21 (33.9%)</td></tr><tr><td align="left">Other (%)</td><td align="left">1 (1.6%)</td></tr><tr><td align="left">PPG before TIPS (mmHg)</td><td align="left">15.00 [13.00, 17.75]</td></tr><tr><td align="left">PPG after TIPS (mmHg)</td><td align="left">6.00 [4.00, 8.00]</td></tr><tr><td align="left"><bold>Stent diameter (%)</bold></td><td align="left"/></tr><tr><td align="left">6</td><td align="left">14 (22.6%)</td></tr><tr><td align="left">7</td><td align="left">1 (1.6%)</td></tr><tr><td align="left">8</td><td align="left">45 (72.6%)</td></tr><tr><td align="left">10</td><td align="left">2 (3.2%)</td></tr><tr><td align="left">MELD (median [IQR])</td><td align="left">10.80 [8.57, 13.74]</td></tr><tr><td align="left">FIPS (median [IQR])</td><td align="left">&#x02212;0.28 [&#x02212;0.74, &#x02212;0.09]</td></tr><tr><td align="left"><bold>Child Pugh (%)</bold></td><td align="left"/></tr><tr><td align="left">A</td><td align="left">10 (16.1%)</td></tr><tr><td align="left">B</td><td align="left">49 (79.0%)</td></tr><tr><td align="left">C</td><td align="left">3 (4.8%)</td></tr><tr><td align="left">Bilirubin (mg/dl)</td><td align="left">0.91 [0.54, 1.51]</td></tr><tr><td align="left">Creatinine (mg/dl)</td><td align="left">1.06 [0.86, 1.34]</td></tr><tr><td align="left">Sodium (mmol/l)</td><td align="left">135.00 [132.00, 137.00]</td></tr><tr><td align="left">Platelets (10<sup>3</sup>/&#x000b5;l)</td><td align="left">115.00 [76.25, 181.75]</td></tr><tr><td align="left">White blood cells (10<sup>3</sup>/&#x000b5;l)</td><td align="left">5.10 [3.80, 6.77]</td></tr><tr><td align="left">CHE (kU/L)</td><td align="left">2.52 [1.86, 4.15]</td></tr><tr><td align="left">Albumin (g/l)</td><td align="left">30.50 [27.25, 36.00]</td></tr><tr><td align="left">AST (U/l)</td><td align="left">37.50 [30.25, 47.75]</td></tr><tr><td align="left">ALT (U/l)</td><td align="left">25.00 [17.00, 33.00]</td></tr><tr><td align="left">Ammonia (&#x000b5;mol/l)</td><td align="left">47.00 [34.00, 69.50]</td></tr><tr><td align="left">CRP (mg/l)</td><td align="left">8.90 [3.40, 19.70]</td></tr><tr><td align="left">Interleukin-6 (pg/ml)</td><td align="left">4.20 [2.32, 8.88]</td></tr><tr><td align="left">Tumor Necrosis Factor alpha (TNF-&#x003b1;) (pg/ml)</td><td align="left">13.20 [10.33, 17.59]</td></tr><tr><td align="left">Interleukin-1 beta (IL-1&#x003b2;) (pg/ml)</td><td align="left">1.29 [1.01, 1.83]</td></tr><tr><td align="left">Diabetes Mellitus (%)</td><td align="left">21 (34.4%)</td></tr><tr><td align="left">History of HE (%)</td><td align="left">15 (24.2%)</td></tr><tr><td align="left">PHES</td><td align="left">&#x02212;6.00 [&#x02212;10.00, &#x02212;4.00]</td></tr><tr><td align="left">Pathological PHES (%)</td><td align="left">36 (67.9%)</td></tr><tr><td align="left">ANT-Score</td><td align="left">19 [15, 24]</td></tr><tr><td align="left">Pathological ANT (%)</td><td align="left">39 (68.4%)</td></tr><tr><td align="left">Any HE prophylaxis at discharge (%)</td><td align="left">51 (82.3%)</td></tr><tr><td align="left">Lactulose (%)</td><td align="left">48 (77.4%)</td></tr><tr><td align="left">Rifaximin (%)</td><td align="left">26 (41.9%)</td></tr><tr><td align="left">L-ornithine L-aspartate (%)</td><td align="left">9 (14.5%)</td></tr><tr><td align="left">Lactulose or Rifaximin (%)</td><td align="left">51 (82.3%)</td></tr></tbody></table><table-wrap-foot><p>* Mixed etiology and indication for TIPS was possible, thus the summation of percentages exceeds 100% in these columns</p><p>Mann-Whitney U test was used for continuous variables, shown with median and IQR, and Chi-squared or Fisher&#x02019;s exact test for categorical variables including percentages</p><p>Abbreviations: TIPS: transjugular intrahepatic portosystemic shunt; ALD: alcohol related liver disease; MetALD: metabolic and alcohol related liver disease; MASLD: metabolic dysfunction-associated steatotic liver disease; MELD: model for end-stage liver disease; FIPS: Freiburg index of post-TIPS survival; PPG: portal pressure gradient; CHE: cholinesterase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CRP: C-reactive protein; HE: hepatic encephalopathy; PHES: psychometric hepatic encephalopathy score; ANT: animal naming test</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Correlation of psychometric test results, mHE and SIM before TIPS insertion</title><p id="Par46">The levels of all SIM (IL-6, TNF-&#x003b1; and IL-1&#x003b2;) before TIPS stratified according to mHE or no mHE at psychometric testing before TIPS were comparable (mHE vs. no mHE: IL-6 4.42 vs. 4.2 pg/ml, <italic>p</italic>&#x02009;=&#x02009;0.493; TNF-&#x003b1; 12.46 vs. 13.82 pg/ml, <italic>p</italic>&#x02009;=&#x02009;0.939; IL-1&#x003b2; 1.29 vs. 1.32 pg/ml, <italic>p</italic>&#x02009;=&#x02009;0.879) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, Suppl. Table <xref rid="MOESM1" ref-type="media">1</xref>). Likewise, none of the investigated SIM showed any statistically significant correlation with PHES or ANT before TIPS (PHES: IL-6 &#x02212;0.87, <italic>p</italic>&#x02009;=&#x02009;0.53; TNF-&#x003b1; &#x02212;0.06, <italic>p</italic>&#x02009;=&#x02009;0.66, IL-1&#x003b2; 0.02, <italic>p</italic>&#x02009;=&#x02009;0.91; ANT: IL-6 &#x02212;0.03, <italic>p</italic>&#x02009;=&#x02009;0.80, TNF-&#x003b1; 0.02, <italic>p</italic>&#x02009;=&#x02009;0.88, IL-1&#x003b2; 0.10, <italic>p</italic>&#x02009;=&#x02009;0.45) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Spearman rho correlations of PHES and ANT with SIM before TIPS-insertion (baseline) and during follow-up</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><bold>Baseline</bold></td><td align="left"/><td align="left"><bold>IL-6</bold></td><td align="left"><bold>TNF-</bold><bold>&#x003b1;</bold></td><td align="left"><bold>IL-1</bold><bold>&#x003b2;</bold></td></tr><tr><td align="left"> PHES</td><td align="left">Correlation coefficient</td><td align="left">&#x02212;0.87</td><td align="left">&#x02212;0.063</td><td align="left">0.016</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.534</td><td align="left">0.656</td><td align="left">0.912</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">53</td><td align="left">53</td><td align="left">53</td></tr><tr><td align="left"> ANT</td><td align="left">Correlation coefficient</td><td align="left">&#x02212;0.34</td><td align="left">0.020</td><td align="left">0.103</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.801</td><td align="left">0.881</td><td align="left">0.446</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">57</td><td align="left">57</td><td align="left">57</td></tr><tr><td align="left"><bold>FU1</bold></td><td align="left"/><td align="left"><bold>IL-6</bold></td><td align="left"><bold>TNF-</bold><bold>&#x003b1;</bold></td><td align="left"><bold>IL-1</bold><bold>&#x003b2;</bold></td></tr><tr><td align="left"> PHES</td><td align="left">Correlation coefficient</td><td align="left">0.193</td><td align="left">0.352</td><td align="left">0.046</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.306</td><td align="left">0.057</td><td align="left">0.810</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">30</td><td align="left">30</td><td align="left">30</td></tr><tr><td align="left"> ANT</td><td align="left">Correlation coefficient</td><td align="left">0.015</td><td align="left">0.126</td><td align="left">&#x02212;0.43</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.939</td><td align="left">0.514</td><td align="left">0.826</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">29</td><td align="left">29</td><td align="left">29</td></tr><tr><td align="left"><bold>FU3</bold></td><td align="left"/><td align="left"><bold>IL-6</bold></td><td align="left"><bold>TNF-</bold><bold>&#x003b1;</bold></td><td align="left"><bold>IL-1</bold><bold>&#x003b2;</bold></td></tr><tr><td align="left"> PHES</td><td align="left">Correlation coefficient</td><td align="left">&#x02212;0.014</td><td align="left">0.092</td><td align="left">0.006</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.932</td><td align="left">0.562</td><td align="left">0.967</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">42</td><td align="left">42</td><td align="left">42</td></tr><tr><td align="left"> ANT</td><td align="left">Correlation coefficient</td><td align="left">&#x02212;0.056</td><td align="left">&#x02212;0.093</td><td align="left">0.156</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.726</td><td align="left">0.556</td><td align="left">0.325</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">42</td><td align="left">42</td><td align="left">42</td></tr><tr><td align="left"><bold>FU6</bold></td><td align="left"/><td align="left"><bold>IL-6</bold></td><td align="left"><bold>TNF-</bold><bold>&#x003b1;</bold></td><td align="left"><bold>IL-1</bold><bold>&#x003b2;</bold></td></tr><tr><td align="left"> PHES</td><td align="left">Correlation coefficient</td><td align="left">&#x02212;0.274</td><td align="left">0.302</td><td align="left">&#x02212;0.063</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.184</td><td align="left">0.143</td><td align="left">0.764</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">25</td><td align="left">25</td><td align="left">25</td></tr><tr><td align="left"> ANT</td><td align="left">Correlation coefficient</td><td align="left">&#x02212;0.107</td><td align="left">0.005</td><td align="left">0.039</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.604</td><td align="left">0.980</td><td align="left">0.849</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">26</td><td align="left">26</td><td align="left">26</td></tr><tr><td align="left"><bold>FU12</bold></td><td align="left"/><td align="left"><bold>IL-6</bold></td><td align="left"><bold>TNF-</bold><bold>&#x003b1;</bold></td><td align="left"><bold>IL-1</bold><bold>&#x003b2;</bold></td></tr><tr><td align="left"> PHES</td><td align="left">Correlation coefficient</td><td align="left">0.103</td><td align="left">0.248</td><td align="left">&#x02212;0.131</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.738</td><td align="left">0.415</td><td align="left">0.669</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">13</td><td align="left">13</td><td align="left">13</td></tr><tr><td align="left"> ANT</td><td align="left">Correlation coefficient</td><td align="left">&#x02212;0.208</td><td align="left">0.466</td><td align="left">0.119</td></tr><tr><td align="left"/><td align="left"><italic>p</italic>-value</td><td align="left">0.495</td><td align="left">0.108</td><td align="left">0.700</td></tr><tr><td align="left"/><td align="left">Number of patients</td><td align="left">13</td><td align="left">13</td><td align="left">13</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: TIPS: transjugular intrahepatic portosystemic shunt; PHES: psychometric hepatic encephalopathy score; ANT: animal naming test; FU: follow-up; IL-6: Interleukin 6; TNF-&#x003b1;: Tumor Necrosis Factor alpha; IL-1&#x003b2;: Interleukin 1 beta</p></table-wrap-foot></table-wrap></p><p id="Par47">
<fig id="Fig2"><label>Fig. 2</label><caption><p><bold>Comparison of levels of IL-6 (A), TNF-&#x003b1; (B) and IL-1&#x003b2; (C) between patients with mHE and patients without mHE before TIPS and their respecive correlation with PHES.</bold> Figure legend: Shown are levels of investigated SIM (IL-6, TNF-&#x003b1;, IL-1&#x003b2;) stratified according to diagnosis of mHE, compared using Mann-Whitney U test, on the left hand side. A linear regression of obtained PHES and respective SIM is displayed on the right hand side of the paired graphs. Psychometric testing yielding the PHES as well as measurement of SIM were conducted before TIPS-insertion. Abbreviations: TIPS: transjugular intrahepatic portosystemic shunt; mHE: minimal hepatic encephalopathy; PHES: psychometric hepatic encephalopathy score; IL-6: Interleukin 6; TNF-&#x003b1;: Tumor Necrosis Factor alpha; IL-1&#x003b2;: Interleukin 1 beta; SIM: soluble inflammatory markers</p></caption><graphic xlink:href="11011_2024_1436_Fig2_HTML" id="d33e1471"/></fig>
</p><p id="Par48">Stratification of PHES in subgroups revealed numerically higher IL-6 in patients with highly pathological scores (&#x02212;11- &#x02212;16: IL-6 8.37 pg/ml) as compared to those with either mildly pathological (-5- -10: IL-6 5.86 pg/ml) or normal test results (IL-6 5.14 pg/ml). The levels of IL-1&#x003b2; and TNF-&#x003b1; did not show any differences across PHES (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, Suppl. Table <xref rid="MOESM1" ref-type="media">2</xref>). Treatment with Rifaximin and Lactulose was not found to impact SIM levels (Suppl. Figure&#x000a0;<xref rid="MOESM1" ref-type="media">7</xref>).</p><p id="Par49">
<fig id="Fig3"><label>Fig. 3</label><caption><p><bold>Comparison of PHES and levels of IL-6 (A), TNF-&#x003b1; (B) and IL-1&#x003b2;&#x000a0;(C) before TIPS insertion.</bold>&#x000a0;Figure legend: Shown are levels of investigated SIM levels (IL-6, TNF-&#x003b1;, IL-1&#x003b2;) stratified according to PHES at time of psychometric testing before TIPS insertion. For comparison of SIM levels Mann-Whitney U test were performed. Abbreviations: TIPS: transjugular intrahepatic portosystemic shunt; PHES: psychometric hepatic encephalopathy score; IL-6: Interleukin 6; TNF-&#x003b1;: Tumor Necrosis Factor alpha; IL-1&#x003b2;: Interleukin 1 beta; n.s.: not statistically significant <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05); SIM: soluble inflammatory markers</p></caption><graphic xlink:href="11011_2024_1436_Fig3_HTML" id="d33e1498"/></fig>
</p><p id="Par50">Two previously proposed cut-offs of IL-6&#x02009;&#x0003e;&#x02009;7 or IL-6&#x02009;&#x0003e;&#x02009;8 pg/ml for stratification of patients with mHE and without likely mHE yielded a sensitivity of 36.1% and 30.6% as well as a specificity of 76.5% and 82.4%, respectively, in our cohort (Suppl. Table <xref rid="MOESM1" ref-type="media">3</xref>).</p></sec><sec id="Sec12"><title>Correlation of psychometric test results, mHE and SIM after TIPS</title><p id="Par51">Both PHES and ANT results showed statistically significant improvements from baseline to FU12 (median PHES &#x02212;&#x02009;6 vs. &#x02212;2.5, <italic>p</italic>&#x02009;=&#x02009;0.007; median ANT 19 vs. 23, <italic>p</italic>&#x02009;=&#x02009;0.004) (Suppl. Figure&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>). Similarly, the percentage of pathological test results obtained during follow-up declined (67.9&#x02013;38.2%, <italic>p</italic>&#x02009;=&#x02009;0.006; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). When comparing the levels of IL-6, TNF-&#x003b1; and IL-1&#x003b2; between patients with mHE and those without at the respective follow-ups, no statistically significant differences between the considered groups became apparent at any time point (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Similarly, correlation analyses of the investigated SIM at the respective follow-ups with the corresponding PHES or ANT did not yield statistically significant results at any of the follow-ups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Suppl. Figure&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>). Co-medication did not impact the levels of SIM at any time point, except for lower levels of TNF-&#x003b1; at FU3 in patients treated with Rifaximin (7.92 vs. 13.07, <italic>p</italic>&#x02009;=&#x02009;0.003, Suppl. Figure&#x000a0;<xref rid="MOESM1" ref-type="media">8</xref>), which was attributable to a lower FU3 MELD in this group (10 vs. 15).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Results of mHE-tests before TIPS-insertion and during follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Baseline (before TIPS)</th><th align="left">FU1 (1 Month)</th><th align="left">FU3 (3 Months)</th><th align="left">FU6 (6 Months)</th><th align="left">FU12 (12 Months)</th></tr></thead><tbody><tr><td align="left">PHES (IQR)</td><td char="(" align="char">&#x02212;6 (&#x02212;10, &#x02212;3.50)</td><td char="(" align="char">&#x02212;7 (&#x02212;10.75, &#x02212;3.25)</td><td char="(" align="char">&#x02212;4 (&#x02212;9.5, &#x02212;2.0)</td><td char="(" align="char">&#x02212;5 (&#x02212;9, &#x02212;3)</td><td char="(" align="char">&#x02212;2.5 (&#x02212;7, 0)</td></tr><tr><td align="left">Pathological PHES (%)</td><td char="(" align="char">36 (67.9%)</td><td char="(" align="char">31 (64.6%)</td><td char="(" align="char">22 (48.9%)</td><td char="(" align="char">19 (57.6%)</td><td char="(" align="char">13 (38.2%)</td></tr><tr><td align="left">ANT (IQR)</td><td char="(" align="char">19 (15, 24.5)</td><td char="(" align="char">19 (14.75,24.5)</td><td char="(" align="char">20 (15, 27.5)</td><td char="(" align="char">22 (15.75, 30.25)</td><td char="(" align="char">23 (18, 27)</td></tr><tr><td align="left">Pathological ANT (%)</td><td char="(" align="char">39 (68.4%)</td><td char="(" align="char">32 (64.0%)</td><td char="(" align="char">24 (53.3%)</td><td char="(" align="char">19 (55.9%)</td><td char="(" align="char">17 (48.6%)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: TIPS: transjugular intrahepatic portosystemic shunt; PHES: psychometric hepatic encephalopathy score; ANT: animal naming test</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Uni- and multivariable competing risk analysis of development of post-TIPS oHE</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2"><italic>n</italic></th><th align="left" colspan="2">Univariable analysis</th><th align="left" colspan="2">Multivariable analysis</th></tr><tr><th align="left">HR (95% CI)</th><th align="left"><italic>p</italic>-value</th><th align="left">HR (95% CI)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">IL-6</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">1.022 (0.943&#x02013;1.109)</td><td char="." align="char">0.59</td><td align="left">1.020 (0.927&#x02013;1.123)</td><td char="." align="char">0.68</td></tr><tr><td align="left">TNF-&#x003b1;</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">0.994 (0.930&#x02013;1.062)</td><td char="." align="char">0.85</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">IL-1&#x003b2;</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">0.750 (0.503&#x02013;1.118)</td><td char="." align="char">0.16</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">Age</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">1.004 (0.961&#x02013;1.050)</td><td char="." align="char">0.85</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">FIPS</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">2.132 (1.099&#x02013;4.135)</td><td char="." align="char"><bold>0.025</bold></td><td align="left">1.988 (0.871&#x02013;4.539)</td><td char="." align="char">0.10</td></tr><tr><td align="left">MELD</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">1.022 (0.903&#x02013;1.157)</td><td char="." align="char">0.73</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">TIPS-indication RA</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">0.547 (0.204&#x02013;1.466)</td><td char="." align="char">0.23</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">Stent diameter (mm)</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">1.496 (1.028&#x02013;2.176)</td><td char="." align="char"><bold>0.035</bold></td><td align="left">1.391 (0.902&#x02013;2.145)</td><td char="." align="char">0.14</td></tr><tr><td align="left">PPG post TIPS (mmHg)</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">0.840 (0.646&#x02013;1.094)</td><td char="." align="char">0.2</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">CHE (kU/l)</td><td char="." align="char"><italic>59</italic></td><td char="." align="char">1.015 (0.751&#x02013;1.372)</td><td char="." align="char">0.92</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">Albumin (g/l)</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">0.905 (0.848&#x02013;0.965)</td><td char="." align="char"><bold>0.002</bold></td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">History of oHE</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">1.387 (0.472&#x02013;4.070)</td><td char="." align="char">0.55</td><td align="left">1.266 (0.389&#x02013;4.117)</td><td char="." align="char">0.69</td></tr><tr><td align="left">Any HE prophylaxis</td><td char="." align="char"><italic>62</italic></td><td char="." align="char">0.477 (0.176&#x02013;1.288)</td><td char="." align="char">0.14</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">PHES before TIPS</td><td char="." align="char"><italic>53</italic></td><td char="." align="char">0.904 (0.805&#x02013;1.014)</td><td char="." align="char">0.085</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">Pathological PHES</td><td char="." align="char"><italic>53</italic></td><td char="." align="char">1.713(0.573&#x02013;5.098)</td><td char="." align="char">0.33</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">ANT before TIPS</td><td char="." align="char"><italic>57</italic></td><td char="." align="char">0.939 (0.880&#x02013;1.003)</td><td char="." align="char">0.063</td><td align="left">-</td><td char="." align="char"/></tr><tr><td align="left">Pathological ANT</td><td char="." align="char"><italic>57</italic></td><td char="." align="char">1.792 (0.600&#x02013;5.367)</td><td char="." align="char">0.3</td><td align="left">-</td><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p>Time-dependent Fine&#x02013;Gray model for competing risk analysis with death or liver transplantation as competing events. 19 (30.6%) patients developed oHE during two-year follow-up. <italic>N</italic>&#x02009;=&#x02009;62 patients were included in multivariable model, in which we adjusted for FIPS and known risk-factors for oHE. As age and albumin are components of the FIPS-Score, they were not included in the multivariable model despite the first being a known-risk factor for oHE</p><p>Values of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 are highlighted in bold font</p><p>Abbreviations: TIPS: transjugular intrahepatic portosystemic shunt; IL-6: Interleukin 6; TNF-&#x003b1;: Tumor Necrosis Factor alpha; IL-1&#x003b2;: Interleukin 1 beta; FIPS: Freiburg index of post-TIPS survival; MELD: model for end-stage liver disease; RA: refractory ascites; PPG: portal pressure gradient; CHE: cholinesterase; oHE: overt hepatic encephalopathy; PHES: psychometric hepatic encephalopathy score; ANT: Animal naming test</p></table-wrap-foot></table-wrap></p><p id="Par52">
<fig id="Fig4"><label>Fig. 4</label><caption><p><bold>Comparison of levels of IL-6 (A), TNF-&#x003b1; (B) and IL-1&#x003b2; (C) between patients with mHE and patients without mHE during follow-up after TIPS.</bold> Figure legend: Shown are levels of investigated SIM (IL-6, TNF-&#x003b1;, IL-1&#x003b2;), stratified according to diagnosis of mHE, at follow-up 1, 3, 6 and 12 months after TIPS-insertion. For group comparisons we used Mann-Whitney-U tests. To improve readability of the figures, two outliers were not pictured (IL-6 no mHE group at FU6&#x02009;=&#x02009;25.84pg/ml, and IL-1&#x003b2;, same group&#x02009;=&#x02009;7.8pg/ml). Abbreviations: TIPS: transjugular intrahepatic portosystemic shunt; mHE: minimal hepatic encephalopathy; IL-6: Interleukin 6; TNF-&#x003b1;: Tumor Necrosis Factor alpha; IL-1&#x003b2;: Interleukin 1 beta; n.s.: not statistically significant; SIM: soluble inflammatory markers</p></caption><graphic xlink:href="11011_2024_1436_Fig4_HTML" id="d33e1931"/></fig>
</p><p id="Par53">Finally, we tested whether a numerical increase of SIM levels between baseline and FU1 or a late FU (3&#x02013;12 months) after TIPS was associated with a corresponding decrease in PHES and found no significant link (Suppl. Figures&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref> and <xref rid="MOESM1" ref-type="media">4</xref>).</p></sec><sec id="Sec13"><title>Predictive value of SIM before TIPS and during follow-up for development of oHE</title><p id="Par54">During two-year follow-up after TIPS-insertion, 19 (30.6%) patients developed an oHE after a median time of 21 days. In univariable competing risk analysis, FIPS (HR 2.13, <italic>p</italic>&#x02009;=&#x02009;0.025), albumin (HR 0.905, <italic>p</italic>&#x02009;=&#x02009;0.002), and larger TIPS-stent-diameter (HR 1.50, <italic>p</italic>&#x02009;=&#x02009;0.04) were associated with oHE, while baseline IL-6, TNF-&#x003b1; and IL-1&#x003b2; were not significantly linked with oHE (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, Suppl. Table <xref rid="MOESM1" ref-type="media">7</xref>).</p><p id="Par55">Previously suggested cut-offs of IL-6&#x02009;&#x0003e;&#x02009;12.75 pg/ml as well as IL-6&#x02009;&#x0003e;&#x02009;10.5 pg/ml before TIPS did not show a statistically significant stratification of patients with a higher cumulative incidence of oHE in follow-up (Tarone-Ware test <italic>p</italic>&#x02009;=&#x02009;0.794 and <italic>p</italic>&#x02009;=&#x02009;0.814, respectively) (Suppl. Figure&#x000a0;<xref rid="MOESM1" ref-type="media">5</xref>).</p><p id="Par56">All investigated SIM showed a statistically significant decrease during follow-up (Suppl. Figure&#x000a0;<xref rid="MOESM1" ref-type="media">6</xref>).</p><p id="Par57">In order to evaluate whether a decrease of SIM is linked with oHE, we then analyzed oHE development both after FU1 and after late FU (3&#x02013;12 months) with consecutive follow-up, respectively. 6/32 (18.8%) patients developed an oHE after FU1 and 6/49 (12.2%) after late FU with a median time to oHE of 113 and 63 days, respectively. Only albumin levels at the respective follow-ups, but neither IL-6-, TNF-&#x003b1;, IL-1&#x003b2;-increase or PHES decrease from pre-TIPS to FU1 or late FU nor MELD and FIPS at the corresponding FU showed significant association with oHE during further follow-up (Suppl. Tables <xref rid="MOESM1" ref-type="media">5</xref>, <xref rid="MOESM1" ref-type="media">6</xref>).</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p id="Par58">The occurrence of overt HE represents a clinically relevant and highly prevalent complication after TIPS-insertion. Psychometric tests for diagnosis of mHE have been proposed as predictor of oHE, but this remains controversial (Berlioux et al. <xref ref-type="bibr" rid="CR5">2014</xref>; Ehrenbauer et al. <xref ref-type="bibr" rid="CR13">2023</xref>; Nardelli et al. <xref ref-type="bibr" rid="CR28">2016</xref>). Lately, the role of systemic inflammation in the pathogenesis of HE has gained increasing recognition (Aldridge et al. <xref ref-type="bibr" rid="CR2">2015</xref>; Arroyo et al. <xref ref-type="bibr" rid="CR4">2021</xref>). As patients treated with a TIPS are generally characterized by a highly progressed liver disease stage, which has been demonstrated to be accompanied by severe systemic inflammation (Arroyo et al. <xref ref-type="bibr" rid="CR4">2021</xref>; Costa et al. <xref ref-type="bibr" rid="CR7">2021</xref>; Engelmann et al. <xref ref-type="bibr" rid="CR14">2021</xref>), we considered the potential relationship between SIM and post-TIPS HE to be of particular interest. Thus, this study investigated the link between psychometric tests and inflammatory markers (SIM) both before and during follow-up after TIPS as well as their predictive value for post-TIPS-oHE.</p><p id="Par59">In the multifactorial pathogenesis of HE, several studies have demonstrated a link between SI and the development of HE (Gairing et al. <xref ref-type="bibr" rid="CR18">2022a</xref>, <xref ref-type="bibr" rid="CR19">2022b</xref>; Labenz et al. <xref ref-type="bibr" rid="CR22">2019</xref>; Shawcross, D. L. et al., <xref ref-type="bibr" rid="CR39">2011</xref>). Most importantly, inflammation is thought to render the brain more susceptible to hyperammonemia by impairing the blood-brain barrier (Aldridge et al. <xref ref-type="bibr" rid="CR2">2015</xref>; de Vires et al. <xref ref-type="bibr" rid="CR11">1996</xref>; Shawcross, Debbie L. et al., <xref ref-type="bibr" rid="CR37">2004</xref>; Shawcross, D. L. et al., <xref ref-type="bibr" rid="CR38">2007</xref>). In-vitro studies have shown a direct disruption of the barrier integrity by IL-6, TNF-&#x003b1; and IL-1&#x003b2; (de Vires et al. <xref ref-type="bibr" rid="CR11">1996</xref>), which is why these particular SIM were selected for the current study. However, TNF-&#x003b1; and IL-1&#x003b2; have not been investigated in this context in clinical setting, so far. Our findings indicate that the effect of these SIM may either not translate from in-vitro to patients with cirrhosis, or the impact of TNF-&#x003b1; and IL-1&#x003b2; could be limited to their secretion by astroglial cells (Aldridge et al. <xref ref-type="bibr" rid="CR2">2015</xref>; de Vires et al. <xref ref-type="bibr" rid="CR11">1996</xref>) and thus not translate to measurably different levels in cubital vein blood. However, our data regarding IL-6 are in contrast to two previously published studies. In concordance with the aforementioned in-vitro data, Shawcross et al. (<xref ref-type="bibr" rid="CR38">2007</xref>) and Gairing et al. (<xref ref-type="bibr" rid="CR18">2022a</xref> ) found significantly higher levels of IL-6 in patients with mHE compared to those without (Gairing et al. <xref ref-type="bibr" rid="CR18">2022a</xref>; Shawcross, D. L. et al., <xref ref-type="bibr" rid="CR38">2007</xref>). We were not able to replicate the above findings and documented only numerically higher IL-6 levels when stratifying for PHES before TIPS-insertion. This may be attributed to our patients&#x02019; characteristics. The study of Gairing et al. included predominantly patients with compensated, Child-Pugh A cirrhosis. The majority of the study cohort published by Shawcross and colleagues had only mild or no ascites. In contrast, almost all of our patients had CHILD B cirrhosis and the far majority were even diagnosed with refractory ascites, which is considered as the advanced, final stage of cirrhosis according to recent classification (D&#x02019;Amico et al. <xref ref-type="bibr" rid="CR9">2018</xref>). Of note, this final stage of cirrhosis is characterized by a high level of systemic inflammation, per se (Costa et al. <xref ref-type="bibr" rid="CR7">2021</xref>). In this state, SIM might be of lower value for the prediction of individual cirrhosis associated complications, particularly for the complex and dynamic syndrome of HE. Compared to earlier stages of liver disease, other factors could be of higher relevance for its pathogenesis, i.e. albumin, which we found to be significantly associated with post-TIPS oHE in all employed statistical models.</p><p id="Par60">During follow-up after TIPS-insertion, the levels of investigated SIM also did not correlate with the presence of mHE or psychometric test results. However, diagnosis of mHE by psychometric testing is only validated for HE type C (European Association for the Study of the Liver <xref ref-type="bibr" rid="CR16">2022</xref>), characterized by a combination of Type A (reduced detoxification) and B (bypassing of detoxification through portosystemic shunt) (Dharel and Bajaj <xref ref-type="bibr" rid="CR12">2015</xref>). It has to be acknowledged that the pathomechanism of HE might change after TIPS insertion. The sudden onset of a large portosystemic shunt might in this setting be of higher importance, similar to a type B rather than a type C HE (Praktiknjo et al. <xref ref-type="bibr" rid="CR31">2020</xref>; Sim&#x000f3;n-Talero et al. <xref ref-type="bibr" rid="CR40">2018</xref>). This hypothesis provides an explanation for the particularly high incidence of oHE in the first month after TIPS, the time most influenced by the new onset of shunting. The statistically significant direct link between larger stent diameter and risk for post-TIPS HE, which we also demonstrated in our study, further supports this hypothesis (Schindler et al. <xref ref-type="bibr" rid="CR34">2020</xref>). Additionally, in lengthy univariable analyses of all SIM, tests, and known risk-factors for oHE, only portosystemic pressure gradient post TIPS (besides albumin) emerged as a statistically relevant risk factor for oHE development after FU1, further indicating that the shunting may be of higher importance for the pathogenesis of post-TIPS oHE than systemic inflammation.</p><p id="Par61">Acknowledging the growing recognition of the role of systemic inflammation in the pathogenesis of HE, a recent investigation by Li et al. (<xref ref-type="bibr" rid="CR25">2023</xref>) found a link between high IL-6 levels pre-TIPS and the development of post-TIPS oHE (Li et al. <xref ref-type="bibr" rid="CR25">2023</xref>). Participants with IL-6&#x02009;&#x0003e;&#x02009;10.5 pg/ml showed a higher incidence of oHE, and a proposed cut-off of 12.75 pg/ml exhibited higher predictive power than other implemented indicators. We did not replicate these findings in our study, most likely due to the significant disparities of patients&#x02019; characteristics, particularly regarding the etiology (majority viral) and indication for TIPS (85% variceal bleeding). As nowadays the majority of TIPS are placed for treatment of refractory ascites (Steib et al. <xref ref-type="bibr" rid="CR41">2020</xref>), our study provides a suitable representation of real-world-setting. Our deviating results underscore the necessity for further research to validate the efficacy of the predictive and diagnostic properties of individual SIM, and emphasize caution regarding the clinical application of SIM.</p><p id="Par62">Systemic inflammation is understood to predominantly result from bacterial translocation from the intestinal lumen due to portal hypertension (Arroyo et al. <xref ref-type="bibr" rid="CR4">2021</xref>; Reiberger et al. <xref ref-type="bibr" rid="CR32">2013</xref>). Thus, TIPS-insertion itself may ameliorate the systemic inflammation as a result of portal pressure reduction. Some studies have shown a reduction of selected SIM, such as CXCL10, following TIPS (Lehmann et al. <xref ref-type="bibr" rid="CR24">2018</xref>). The investigated SIM IL-6, TNF-&#x003b1; and IL-1&#x003b2; in our study collectively show a steady decrease following TIPS-insertion, thereby suggesting an effect of TIPS on systemic inflammation. However, SIM changes did not correlate with changes in the psychometric tests or oHE development. This may be attributable to the aforementioned rather complex multifactorial pathomechanism of post-TIPS HE and the decreasing cohort size during further follow-up due to the high mortality in patients with decompensated cirrhosis.</p><p id="Par63">Our study has some limitations. Firstly, the above-mentioned relatively small sample size in our study may have translated to a lack of statistical power to detect smaller differences regarding the predictive value of SIM or the correlation of tests and SIM. Secondly, we excluded patients with active infections and hemodialysis before TIPS and during follow-up, thus limiting the generalizability of our results. However, these comorbidities can lead to cognitive deficits per se, which may affect psychometric tests and may not be distinguishable from hepatic encephalopathy. Lastly, despite providing a hypothesis for a reduced risk for post-TIPS HE as a result of a TIPS-mediated amelioration of investigated SIM, this study was not designed to explore the pathomechanism of post-TIPS HE and provide reasoning as to why the incidence of HE post TIPS is elevated despite reduced systemic inflammation. The exploration of this matter remains of high interest for further studies.</p><p id="Par64">In conclusion, our study did not demonstrate a significant link between IL-6, TNF-&#x003b1; and IL-1&#x003b2; and psychometric tests before TIPS and during follow-up thereafter. We found no predictive value of pre-TIPS SIM levels, but a significant decrease of systemic inflammation after TIPS. However, this did not translate to a reduced risk for post-TIPS oHE. Hence, the pathomechanism and predictors for post-TIPS HE remain of particular interest for future studies.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11011_2024_1436_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ANT</term><def><p id="Par2">animal naming test</p></def></def-item><def-item><term>ALD</term><def><p id="Par3">alcohol related liver disease</p></def></def-item><def-item><term>CHE</term><def><p id="Par4">cholinesterase</p></def></def-item><def-item><term>FIPS</term><def><p id="Par5">Freiburg index of post-TIPS survival</p></def></def-item><def-item><term>FU</term><def><p id="Par6">follow-up after TIPS</p></def></def-item><def-item><term>HE</term><def><p id="Par7">hepatic encephalopathy</p></def></def-item><def-item><term>HR</term><def><p id="Par8">hazard ratio</p></def></def-item><def-item><term>IL-6</term><def><p id="Par9">Interleukin 6</p></def></def-item><def-item><term>IL-1&#x003b2;</term><def><p id="Par10">Interleukin 1-beta</p></def></def-item><def-item><term>ISHEN</term><def><p id="Par11">International Society for Hepatic Encephalopathy and Nitrogen Metabolism</p></def></def-item><def-item><term>MASLD</term><def><p id="Par12">metabolic dysfunction-associated steatotic liver disease</p></def></def-item><def-item><term>MELD</term><def><p id="Par13">model for end-stage liver disease</p></def></def-item><def-item><term>MetALD</term><def><p id="Par14">metabolic and alcohol related liver disease</p></def></def-item><def-item><term>mHE</term><def><p id="Par15">minimal hepatic encephalopathy</p></def></def-item><def-item><term>oHE</term><def><p id="Par16">overt hepatic encephalopathy</p></def></def-item><def-item><term>PHES</term><def><p id="Par17">psychometric hepatic encephalopathy score</p></def></def-item><def-item><term>PSE</term><def><p id="Par18">portosystemic encephalopathy syndrome test</p></def></def-item><def-item><term>PPG</term><def><p id="Par19">portal pressure gradient</p></def></def-item><def-item><term>TIPS</term><def><p id="Par20">transjugular intrahepatic portosystemic shunt</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par21">Tumor Necrosis Factor alpha</p></def></def-item><def-item><term>SIM</term><def><p id="Par22">soluble inflammatory marker</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Jennifer Witt and Charlotte Lorenz for their support in recruiting and examining patients as well as Jim Mauz, Lea Wagner and Martin Kabelitz for support in data curation. We also extend our thanks to Birgit Bremer, Helena Lickei and Hagen Schmaus for their assistance in sample processing and measurement of systemic inflammatory markers.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualisation: Benjamin Maasoumy, Anja Tiede</p><p>Formal analysis: Anja Tiede, Christine S. Falk</p><p>Data curation: Anja Tiede, Lena Stockhoff, Alena F. Ehrenbauer, Hannah Rieland, Christine S. Falk</p><p>Investigation: Anja Tiede, Lena Stockhoff, Alena F. Ehrenbauer, Hannah Rieland, Jan B. Hinrichs, Christine S. Falk</p><p>Methodology: Benjamin Maasoumy, Karin Weissenborn, Anja Tiede</p><p>Project Administration: Benjamin Maasoumy, Anja Tiede, Lena Stockhoff, Hannah Rieland</p><p>Resources: Anja Tiede, Lena Stockhoff, Alena F. Ehrenbauer, Hannah Rieland, Markus Cornberg, Bernhard C. Meyer, Heiner Wedemeyer, Hinrichs, Maria M. Gabriel, Christine S. Falk, Benjamin Maasoumy</p><p>Supervision: Benjamin Maasoumy, Karin Weissenborn, Markus Cornberg, Jan B. Hinrichs </p><p>Visualisation: Anja Tiede</p><p>Writing&#x02013; original draft: Anja Tiede, Benjamin Maasoumy</p><p>Writing&#x02013; review and editing: Anja Tiede, Benjamin Maasoumy, Karin Weissenborn, Lena Stockhoff, Alena F. Ehrenbauer, Hannah Rieland, Jan B. Hinrichs, Maria M. Gabriel</p><p>All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Anja Tiede, Hannah Rieland, Lena Stockhoff and Alena F. Ehrenbauer were supported by the &#x0201e;KlinStrucMed&#x0201c;program of the Hannover Medical School and by the &#x0201e;Elser-Kr&#x000f6;ner-Fresenius-Stiftung&#x0201d;. Maria M. Gabriel was funded by the Ellen-Schmidt-Scholarship of Hannover Medical School. Anja Tiede and Benjamin Maasoumy received funding from the MHHplus foundation. This study was partly supported by the German Center for Infection Research (TTU 06.910).</p><p>Open Access funding enabled and organized by Projekt DEAL.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Anonymised data of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval&#x000a0;&#x00026; consent</title><p id="Par65">All patients gave written informed consent to enroll in this prospective study, registered at ClinicalTrials.gov (trial number: NCT04801290). The local ethics committee of Hannover Medical School approved this study (protocol identification number: Nr. 8498_BO_S_2019), which was conducted according to the principles of the Declaration of Helsinki.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par66">Karin Weissenborn: Development of the Psychometric Hepatic Encephalopathy Score (PHES); the copyright of the test is held by Hannover Medical School.</p><p id="Par67">Heiner Wedemeyer: Biotest AG (Grants, Consulting), Dr. Falk Pharma (Clinical Trials, Consulting), Norgine (Counsulting, Lectures), Merck KGaA (Consulting, Lectures), Gilead (Clinical Trials, Grants, Consulting, Lectures), Roche (Consulting).</p><p id="Par68">Markus Cornberg: AbbVie (Consulting, Lectures), AiCuris (Consulting), Falk (Lectures), Gilead (Consulting, Lectures), GlaxoSmithKline (GSK) (Consulting, Lectures), Janssen (Consulting), Merck/MSD (Consulting, Lectures), Novartis (Consulting), Roche (Consulting), Swedish Orphan Biovitrum (SOBI) (Consulting).</p><p id="Par69">Benjamin Maasoumy: MSD (Lectures), Falk (Lectures), AbbVie (Lectures, Consulting), Astellas (Lectures), Medical Tribune (Lectures), Norgine (Lectures, Consulting), Fujirebio (Lectures, Research Grants), Roche (Lectures, Consulting, Research Grants), Gilead (Lectures), Gore (Lectures), Luvos (Consulting), Altona Diagnostics (Research Grants).</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Agrawal S, Umapathy S, Dhiman RK (2015) Minimal hepatic Encephalopathy impairs Quality of Life. J Clin Experimental Hepatol 5S42&#x02013;S48. 10.1016/j.jceh.2014.11.006</mixed-citation></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Aldridge</surname><given-names>DR</given-names></name><name><surname>Tranah</surname><given-names>EJ</given-names></name><name><surname>Shawcross</surname><given-names>DL</given-names></name></person-group><article-title>Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation</article-title><source>J Clin Exp Hepatol</source><year>2015</year><volume>5</volume><fpage>S7</fpage><lpage>S20</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2014.06.004</pub-id><pub-id pub-id-type="pmid">26041962</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Aldridge DR, Tranah EJ, Shawcross DL (2015) Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol 5:S7&#x02013;S20. 10.1016/j.jceh.2014.06.004<pub-id pub-id-type="pmid">26041962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Ampuero</surname><given-names>J</given-names></name><name><surname>Montoli&#x000fa;</surname><given-names>C</given-names></name><name><surname>Sim&#x000f3;n-Talero</surname><given-names>M</given-names></name><name><surname>Aguilera</surname><given-names>V</given-names></name><name><surname>Mill&#x000e1;n</surname><given-names>R</given-names></name><name><surname>M&#x000e1;rquez</surname><given-names>C</given-names></name><name><surname>Jover</surname><given-names>R</given-names></name><name><surname>Rico</surname><given-names>MC</given-names></name><name><surname>Sendra</surname><given-names>C</given-names></name><name><surname>Serra</surname><given-names>M&#x000c1;</given-names></name><name><surname>Romero-G&#x000f3;mez</surname><given-names>M</given-names></name></person-group><article-title>Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression</article-title><source>J Gastroenterol Hepatol</source><year>2018</year><volume>33</volume><fpage>718</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1111/jgh.13917</pub-id><pub-id pub-id-type="pmid">28768371</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ampuero J, Montoli&#x000fa; C, Sim&#x000f3;n-Talero M, Aguilera V, Mill&#x000e1;n R, M&#x000e1;rquez C, Jover R, Rico MC, Sendra C, Serra M&#x000c1;, Romero-G&#x000f3;mez M (2018) Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. J Gastroenterol Hepatol 33:718&#x02013;725. 10.1111/jgh.13917<pub-id pub-id-type="pmid">28768371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Arroyo</surname><given-names>V</given-names></name><name><surname>Angeli</surname><given-names>P</given-names></name><name><surname>Moreau</surname><given-names>R</given-names></name><name><surname>Jalan</surname><given-names>R</given-names></name><name><surname>Cl&#x000e0;ria</surname><given-names>J</given-names></name><name><surname>Trebicka</surname><given-names>J</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>J</given-names></name><name><surname>Gustot</surname><given-names>T</given-names></name><name><surname>Caraceni</surname><given-names>P</given-names></name><name><surname>Bernardi</surname><given-names>M</given-names></name></person-group><article-title>The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis</article-title><source>J Hepatol</source><year>2021</year><volume>74</volume><fpage>670</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.11.048</pub-id><pub-id pub-id-type="pmid">33301825</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Arroyo V, Angeli P, Moreau R, Jalan R, Cl&#x000e0;ria J, Trebicka J, Fern&#x000e1;ndez J, Gustot T, Caraceni P, Bernardi M (2021) The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol 74:670&#x02013;685. 10.1016/j.jhep.2020.11.048<pub-id pub-id-type="pmid">33301825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Berlioux</surname><given-names>P</given-names></name><name><surname>Robic</surname><given-names>MA</given-names></name><name><surname>Poirson</surname><given-names>H</given-names></name><name><surname>M&#x000e9;tivier</surname><given-names>S</given-names></name><name><surname>Otal</surname><given-names>P</given-names></name><name><surname>Barret</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>F</given-names></name><name><surname>P&#x000e9;ron</surname><given-names>JM</given-names></name><name><surname>Vinel</surname><given-names>JP</given-names></name><name><surname>Bureau</surname><given-names>C</given-names></name></person-group><article-title>Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post&#x02010;TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests</article-title><source>Hepatology (Baltimore MD)</source><year>2014</year><volume>59</volume><fpage>622</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1002/hep.26684</pub-id><pub-id pub-id-type="pmid">24620380</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Berlioux P, Robic MA, Poirson H, M&#x000e9;tivier S, Otal P, Barret C, Lopez F, P&#x000e9;ron JM, Vinel JP, Bureau C (2014) Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post&#x02010;TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology (Baltimore MD) 59:622&#x02013;629. 10.1002/hep.26684<pub-id pub-id-type="pmid">24620380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Campagna</surname><given-names>F</given-names></name><name><surname>Montagnese</surname><given-names>S</given-names></name><name><surname>Ridola</surname><given-names>L</given-names></name><name><surname>Senzolo</surname><given-names>M</given-names></name><name><surname>Schiff</surname><given-names>S</given-names></name><name><surname>De Rui</surname><given-names>M</given-names></name><name><surname>Pasquale</surname><given-names>C</given-names></name><name><surname>Nardelli</surname><given-names>S</given-names></name><name><surname>Pentassuglio</surname><given-names>I</given-names></name><name><surname>Merkel</surname><given-names>C</given-names></name><name><surname>Angeli</surname><given-names>P</given-names></name><name><surname>Riggio</surname><given-names>O</given-names></name><name><surname>Amodio</surname><given-names>P</given-names></name></person-group><article-title>The animal naming test: an easy tool for the assessment of hepatic encephalopathy</article-title><source>Hepatology</source><year>2017</year><volume>66</volume><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1002/hep.29146</pub-id><pub-id pub-id-type="pmid">28271528</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Campagna F, Montagnese S, Ridola L, Senzolo M, Schiff S, De Rui M, Pasquale C, Nardelli S, Pentassuglio I, Merkel C, Angeli P, Riggio O, Amodio P (2017) The animal naming test: an easy tool for the assessment of hepatic encephalopathy. Hepatology 66:198&#x02013;208. 10.1002/hep.29146<pub-id pub-id-type="pmid">28271528</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Simbrunner</surname><given-names>B</given-names></name><name><surname>Jachs</surname><given-names>M</given-names></name><name><surname>Hartl</surname><given-names>L</given-names></name><name><surname>Bauer</surname><given-names>D</given-names></name><name><surname>Paternostro</surname><given-names>R</given-names></name><name><surname>Schwabl</surname><given-names>P</given-names></name><name><surname>Scheiner</surname><given-names>B</given-names></name><name><surname>St&#x000e4;ttermayer</surname><given-names>AF</given-names></name><name><surname>Pinter</surname><given-names>M</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name><name><surname>Mandorfer</surname><given-names>M</given-names></name><name><surname>Reiberger</surname><given-names>T</given-names></name></person-group><article-title>Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality</article-title><source>J Hepatol</source><year>2021</year><volume>74</volume><fpage>819</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.10.004</pub-id><pub-id pub-id-type="pmid">33075344</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, St&#x000e4;ttermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T (2021) Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol 74:819&#x02013;828. 10.1016/j.jhep.2020.10.004<pub-id pub-id-type="pmid">33075344</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amico</surname><given-names>G</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name><surname>Pagliaro</surname><given-names>L</given-names></name></person-group><article-title>Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies</article-title><source>J Hepatol</source><year>2006</year><volume>44</volume><fpage>217</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2005.10.013</pub-id><pub-id pub-id-type="pmid">16298014</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">D&#x02019;Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217&#x02013;231. 10.1016/j.jhep.2005.10.013<pub-id pub-id-type="pmid">16298014</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amico</surname><given-names>G</given-names></name><name><surname>Morabito</surname><given-names>A</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>M</given-names></name><name><surname>Pasta</surname><given-names>L</given-names></name><name><surname>Malizia</surname><given-names>G</given-names></name><name><surname>Rebora</surname><given-names>P</given-names></name><name><surname>Valsecchi</surname><given-names>MG</given-names></name></person-group><article-title>Clinical states of cirrhosis and competing risks</article-title><source>J Hepatol</source><year>2018</year><volume>68</volume><fpage>563</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.10.020</pub-id><pub-id pub-id-type="pmid">29111320</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">D&#x02019;Amico G, Morabito A, D&#x02019;Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG (2018) Clinical states of cirrhosis and competing risks. J Hepatol 68:563&#x02013;576. 10.1016/j.jhep.2017.10.020<pub-id pub-id-type="pmid">29111320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>de Franchis</surname><given-names>R</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name><surname>Reiberger</surname><given-names>T</given-names></name><name><surname>Ripoll</surname><given-names>C</given-names></name></person-group><article-title>Baveno VII - renewing consensus in portal hypertension: personalized care for portal hypertension</article-title><source>J Hepatol</source><year>2022</year><volume>30</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3760/cma.j.cn501113-20220109-00010</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C (2022) Baveno VII - renewing consensus in portal hypertension: personalized care for portal hypertension. J Hepatol 30:21&#x02013;29. 10.3760/cma.j.cn501113-20220109-00010</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>de Vires</surname><given-names>HE</given-names></name><name><surname>Blom-Roosemalen</surname><given-names>MC</given-names></name><name><surname>van Oosten</surname><given-names>M</given-names></name><name><surname>de Boer</surname><given-names>AG</given-names></name><name><surname>van Berkel</surname><given-names>TJ</given-names></name><name><surname>Breimer</surname><given-names>DD</given-names></name><name><surname>Kuiper</surname><given-names>J</given-names></name></person-group><article-title>The influence of cytokines on the integrity of the blood-brain barrier in vitro</article-title><source>J Neuroimmunol</source><year>1996</year><pub-id pub-id-type="doi">10.1016/0165-5728(95)00148-4</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">de Vires HE, Blom-Roosemalen MC, van Oosten M, de Boer AG, van Berkel TJ, Breimer DD, Kuiper J (1996) The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 10.1016/0165-5728(95)00148-4</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Dharel</surname><given-names>N</given-names></name><name><surname>Bajaj</surname><given-names>JS</given-names></name></person-group><article-title>Definition and nomenclature of hepatic Encephalopathy</article-title><source>J Clin Experimental Hepatol</source><year>2015</year><volume>5</volume><fpage>S37</fpage><lpage>S41</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2014.10.001</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Dharel N, Bajaj JS (2015) Definition and nomenclature of hepatic Encephalopathy. J Clin Experimental Hepatol 5:S37&#x02013;S41. 10.1016/j.jceh.2014.10.001</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrenbauer</surname><given-names>AF</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Stockhoff</surname><given-names>L</given-names></name><name><surname>Tiede</surname><given-names>A</given-names></name><name><surname>Lorenz</surname><given-names>C</given-names></name><name><surname>Dirks</surname><given-names>M</given-names></name><name><surname>Witt</surname><given-names>J</given-names></name><name><surname>Gabriel</surname><given-names>MM</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Hinrichs</surname><given-names>JB</given-names></name><name><surname>Weissenborn</surname><given-names>K</given-names></name><name><surname>Maasoumy</surname><given-names>B</given-names></name></person-group><article-title>Predicting overt hepatic encephalopathy after TIPS: value of three minimal hepatic encephalopathy tests</article-title><source>JHEP Rep</source><year>2023</year><volume>5</volume><fpage>100829</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2023.100829</pub-id><pub-id pub-id-type="pmid">37600959</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ehrenbauer AF, Schneider H, Stockhoff L, Tiede A, Lorenz C, Dirks M, Witt J, Gabriel MM, Wedemeyer H, Hinrichs JB, Weissenborn K, Maasoumy B (2023) Predicting overt hepatic encephalopathy after TIPS: value of three minimal hepatic encephalopathy tests. JHEP Rep 5:100829. 10.1016/j.jhepr.2023.100829<pub-id pub-id-type="pmid">37600959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Engelmann</surname><given-names>C</given-names></name><name><surname>Cl&#x000e0;ria</surname><given-names>J</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>Bernardi</surname><given-names>M</given-names></name></person-group><article-title>Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><fpage>S49</fpage><lpage>S66</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.01.002</pub-id><pub-id pub-id-type="pmid">34039492</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Engelmann C, Cl&#x000e0;ria J, Szabo G, Bosch J, Bernardi M (2021) Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol 75:S49&#x02013;S66. 10.1016/j.jhep.2021.01.002<pub-id pub-id-type="pmid">34039492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL Clinical Practice guidelines for the management of patients with decompensated cirrhosis</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>406</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.024</pub-id><pub-id pub-id-type="pmid">29653741</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69:406&#x02013;460. 10.1016/j.jhep.2018.03.024<pub-id pub-id-type="pmid">29653741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL Clinical Practice guidelines on the management of hepatic encephalopathy</article-title><source>J Hepatol</source><year>2022</year><volume>77</volume><fpage>807</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2022.06.001</pub-id><pub-id pub-id-type="pmid">35724930</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">European Association for the Study of the Liver (2022) EASL Clinical Practice guidelines on the management of hepatic encephalopathy. J Hepatol 77:807&#x02013;824. 10.1016/j.jhep.2022.06.001<pub-id pub-id-type="pmid">35724930</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Flud</surname><given-names>CR</given-names></name><name><surname>Duarte-Rojo</surname><given-names>A</given-names></name></person-group><article-title>Prognostic implications of Minimal/Covert hepatic encephalopathy: large-scale validation cohort studies</article-title><source>J Clin Exp Hepatol</source><year>2019</year><volume>9</volume><fpage>112</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2018.04.009</pub-id><pub-id pub-id-type="pmid">30765944</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Flud CR, Duarte-Rojo A (2019) Prognostic implications of Minimal/Covert hepatic encephalopathy: large-scale validation cohort studies. J Clin Exp Hepatol 9:112&#x02013;116. 10.1016/j.jceh.2018.04.009<pub-id pub-id-type="pmid">30765944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Gairing</surname><given-names>SJ</given-names></name><name><surname>Anders</surname><given-names>J</given-names></name><name><surname>Kaps</surname><given-names>L</given-names></name><name><surname>Nagel</surname><given-names>M</given-names></name><name><surname>Michel</surname><given-names>M</given-names></name><name><surname>Kremer</surname><given-names>WM</given-names></name><name><surname>Hilscher</surname><given-names>M</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Schattenberg</surname><given-names>JM</given-names></name><name><surname>W&#x000f6;rns</surname><given-names>M</given-names></name><name><surname>Labenz</surname><given-names>C</given-names></name></person-group><article-title>Evaluation of IL-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis</article-title><source>Hepatol Commun</source><year>2022</year><volume>6</volume><fpage>1113</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1002/hep4.1883</pub-id><pub-id pub-id-type="pmid">35032100</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gairing SJ, Anders J, Kaps L, Nagel M, Michel M, Kremer WM, Hilscher M, Galle PR, Schattenberg JM, W&#x000f6;rns M, Labenz C (2022a) Evaluation of IL-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol Commun 6:1113&#x02013;1122. 10.1002/hep4.1883<pub-id pub-id-type="pmid">35032100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Gairing</surname><given-names>SJ</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>L</given-names></name><name><surname>Kloeckner</surname><given-names>R</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Labenz</surname><given-names>C</given-names></name></person-group><article-title>Review article: post-TIPSS hepatic encephalopathy&#x02014;current knowledge and future perspectives</article-title><source>Aliment Pharmacol Ther</source><year>2022</year><volume>55</volume><fpage>1265</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1111/apt.16825</pub-id><pub-id pub-id-type="pmid">35181894</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gairing SJ, M&#x000fc;ller L, Kloeckner R, Galle PR, Labenz C (2022b) Review article: post-TIPSS hepatic encephalopathy&#x02014;current knowledge and future perspectives. Aliment Pharmacol Ther 55:1265&#x02013;1276. 10.1111/apt.16825<pub-id pub-id-type="pmid">35181894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Pag&#x000e1;n</surname><given-names>JC</given-names></name><name><surname>Saffo</surname><given-names>S</given-names></name><name><surname>Mandorfer</surname><given-names>M</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name></person-group><article-title>Where does TIPS fit in the management of patients with cirrhosis?</article-title><source>JHEP Rep</source><year>2020</year><volume>2</volume><fpage>100122</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2020.100122</pub-id><pub-id pub-id-type="pmid">32671331</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Garc&#x000ed;a-Pag&#x000e1;n JC, Saffo S, Mandorfer M, Garcia-Tsao G (2020) Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep 2:100122. 10.1016/j.jhepr.2020.100122<pub-id pub-id-type="pmid">32671331</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Labenz</surname><given-names>C</given-names></name><name><surname>Schattenberg</surname><given-names>JM</given-names></name></person-group><article-title>Animal naming test - animals as diagnostic solution?</article-title><source>Z Gastroenterol</source><year>2018</year><volume>56</volume><fpage>168</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1055/s-0043-117268</pub-id><pub-id pub-id-type="pmid">29415316</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Labenz C, Schattenberg JM (2018) Animal naming test - animals as diagnostic solution? Z Gastroenterol 56:168&#x02013;169. 10.1055/s-0043-117268<pub-id pub-id-type="pmid">29415316</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Labenz</surname><given-names>C</given-names></name><name><surname>Toenges</surname><given-names>G</given-names></name><name><surname>Huber</surname><given-names>Y</given-names></name><name><surname>Nagel</surname><given-names>M</given-names></name><name><surname>Marquardt</surname><given-names>JU</given-names></name><name><surname>Schattenberg</surname><given-names>JM</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Labenz</surname><given-names>J</given-names></name><name><surname>W&#x000f6;rns</surname><given-names>M</given-names></name></person-group><article-title>Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy</article-title><source>Aliment Pharmacol Ther</source><year>2019</year><volume>50</volume><fpage>1112</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1111/apt.15515</pub-id><pub-id pub-id-type="pmid">31583743</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, Galle PR, Labenz J, W&#x000f6;rns M (2019) Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Aliment Pharmacol Ther 50:1112&#x02013;1119. 10.1111/apt.15515<pub-id pub-id-type="pmid">31583743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Larrue</surname><given-names>H</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>G</given-names></name><name><surname>Olivas</surname><given-names>P</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Bucsics</surname><given-names>T</given-names></name><name><surname>Rudler</surname><given-names>M</given-names></name><name><surname>Sauerbruch</surname><given-names>T</given-names></name><name><surname>Hernandez-Gea</surname><given-names>V</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Reiberger</surname><given-names>T</given-names></name><name><surname>Thabut</surname><given-names>D</given-names></name><name><surname>Vinel</surname><given-names>J</given-names></name><name><surname>P&#x000e9;ron</surname><given-names>J</given-names></name><name><surname>Garc&#x000ed;a-Pag&#x000e1;n</surname><given-names>J</given-names></name><name><surname>Bureau</surname><given-names>C</given-names></name></person-group><article-title>TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><fpage>692</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.04.028</pub-id><pub-id pub-id-type="pmid">37141993</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Larrue H, D&#x02019;Amico G, Olivas P, Lv Y, Bucsics T, Rudler M, Sauerbruch T, Hernandez-Gea V, Han G, Reiberger T, Thabut D, Vinel J, P&#x000e9;ron J, Garc&#x000ed;a-Pag&#x000e1;n J, Bureau C (2023) TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. J Hepatol 79:692&#x02013;703. 10.1016/j.jhep.2023.04.028<pub-id pub-id-type="pmid">37141993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>JM</given-names></name><name><surname>Claus</surname><given-names>K</given-names></name><name><surname>Jansen</surname><given-names>C</given-names></name><name><surname>Pohlmann</surname><given-names>A</given-names></name><name><surname>Schierwagen</surname><given-names>R</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Manekeller</surname><given-names>S</given-names></name><name><surname>Claria</surname><given-names>J</given-names></name><name><surname>Strassburg</surname><given-names>CP</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Wasmuth</surname><given-names>HE</given-names></name><name><surname>Berres</surname><given-names>M</given-names></name><name><surname>Trebicka</surname><given-names>J</given-names></name></person-group><article-title>Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality</article-title><source>Liver Int</source><year>2018</year><volume>38</volume><fpage>875</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1111/liv.13610</pub-id><pub-id pub-id-type="pmid">29105936</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Lehmann JM, Claus K, Jansen C, Pohlmann A, Schierwagen R, Meyer C, Thomas D, Manekeller S, Claria J, Strassburg CP, Trautwein C, Wasmuth HE, Berres M, Trebicka J (2018) Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. Liver Int 38:875&#x02013;884. 10.1111/liv.13610<pub-id pub-id-type="pmid">29105936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><mixed-citation publication-type="other">Li J, Liu Y, Li M, Rong X, Yuan Z, Ren C, Liu S, Li L, Zhao C, Gao L, Feng D (2023) Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS. Hepatol Commun 7. 10.1097/HC9.0000000000000128</mixed-citation></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Marquardt</surname><given-names>S</given-names></name><name><surname>Rodt</surname><given-names>T</given-names></name><name><surname>Rosenthal</surname><given-names>H</given-names></name><name><surname>Wacker</surname><given-names>F</given-names></name><name><surname>Meyer</surname><given-names>BC</given-names></name></person-group><article-title>Impact of anatomical, procedural, and Operator Skill factors on the success and duration of Fluoroscopy-guided Transjugular Intrahepatic Portosystemic Shunt</article-title><source>Cardiovasc Intervent Radiol</source><year>2015</year><volume>38</volume><fpage>903</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1007/s00270-014-1035-6</pub-id><pub-id pub-id-type="pmid">25501265</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Marquardt S, Rodt T, Rosenthal H, Wacker F, Meyer BC (2015) Impact of anatomical, procedural, and Operator Skill factors on the success and duration of Fluoroscopy-guided Transjugular Intrahepatic Portosystemic Shunt. Cardiovasc Intervent Radiol 38:903&#x02013;912. 10.1007/s00270-014-1035-6<pub-id pub-id-type="pmid">25501265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Meine</surname><given-names>TC</given-names></name><name><surname>Dewald</surname><given-names>CLA</given-names></name><name><surname>Becker</surname><given-names>LS</given-names></name><name><surname>M&#x000e4;hringer-Kunz</surname><given-names>A</given-names></name><name><surname>Maasoumy</surname><given-names>B</given-names></name><name><surname>Maschke</surname><given-names>SK</given-names></name><name><surname>Kirstein</surname><given-names>MM</given-names></name><name><surname>Werncke</surname><given-names>T</given-names></name><name><surname>Wacker</surname><given-names>FK</given-names></name><name><surname>Meyer</surname><given-names>BC</given-names></name><name><surname>Hinrichs</surname><given-names>JB</given-names></name></person-group><article-title>Transjugular intrahepatic portosystemic shunt placement: portal vein puncture guided by 3D/2D image registration of contrast-enhanced multi-detector computed tomography and fluoroscopy</article-title><source>Abdom Radiol</source><year>2020</year><volume>45</volume><fpage>3934</fpage><lpage>3943</lpage><pub-id pub-id-type="doi">10.1007/s00261-020-02589-1</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Meine TC, Dewald CLA, Becker LS, M&#x000e4;hringer-Kunz A, Maasoumy B, Maschke SK, Kirstein MM, Werncke T, Wacker FK, Meyer BC, Hinrichs JB (2020) Transjugular intrahepatic portosystemic shunt placement: portal vein puncture guided by 3D/2D image registration of contrast-enhanced multi-detector computed tomography and fluoroscopy. Abdom Radiol 45:3934&#x02013;3943. 10.1007/s00261-020-02589-1</mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Nardelli</surname><given-names>S</given-names></name><name><surname>Gioia</surname><given-names>S</given-names></name><name><surname>Pasquale</surname><given-names>C</given-names></name><name><surname>Pentassuglio</surname><given-names>I</given-names></name><name><surname>Farcomeni</surname><given-names>A</given-names></name><name><surname>Merli</surname><given-names>M</given-names></name><name><surname>Salvatori</surname><given-names>FM</given-names></name><name><surname>Nikolli</surname><given-names>L</given-names></name><name><surname>Torrisi</surname><given-names>S</given-names></name><name><surname>Greco</surname><given-names>F</given-names></name><name><surname>Nicoletti</surname><given-names>V</given-names></name><name><surname>Riggio</surname><given-names>O</given-names></name></person-group><article-title>Cognitive impairment predicts the occurrence of hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt</article-title><source>Am J Gastroenterol</source><year>2016</year><volume>111</volume><fpage>523</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/ajg.2016.29</pub-id><pub-id pub-id-type="pmid">26925879</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Nardelli S, Gioia S, Pasquale C, Pentassuglio I, Farcomeni A, Merli M, Salvatori FM, Nikolli L, Torrisi S, Greco F, Nicoletti V, Riggio O (2016) Cognitive impairment predicts the occurrence of hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt. Am J Gastroenterol 111:523&#x02013;528. 10.1038/ajg.2016.29<pub-id pub-id-type="pmid">26925879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Nardelli</surname><given-names>S</given-names></name><name><surname>Riggio</surname><given-names>O</given-names></name><name><surname>Marra</surname><given-names>F</given-names></name><name><surname>Gioia</surname><given-names>S</given-names></name><name><surname>Saltini</surname><given-names>D</given-names></name><name><surname>Bellafante</surname><given-names>D</given-names></name><name><surname>Adotti</surname><given-names>V</given-names></name><name><surname>Guasconi</surname><given-names>T</given-names></name><name><surname>Ridola</surname><given-names>L</given-names></name><name><surname>Rosi</surname><given-names>M</given-names></name><name><surname>Caporali</surname><given-names>C</given-names></name><name><surname>Fanelli</surname><given-names>F</given-names></name><name><surname>Roccarina</surname><given-names>D</given-names></name><name><surname>Bianchini</surname><given-names>M</given-names></name><name><surname>Indulti</surname><given-names>F</given-names></name><name><surname>Spagnoli</surname><given-names>A</given-names></name><name><surname>Merli</surname><given-names>M</given-names></name><name><surname>Vizzutti</surname><given-names>F</given-names></name><name><surname>Schepis</surname><given-names>F</given-names></name></person-group><article-title>Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis</article-title><source>J Hepatol</source><year>2024</year><volume>80</volume><fpage>596</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.11.033</pub-id><pub-id pub-id-type="pmid">38097113</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Nardelli S, Riggio O, Marra F, Gioia S, Saltini D, Bellafante D, Adotti V, Guasconi T, Ridola L, Rosi M, Caporali C, Fanelli F, Roccarina D, Bianchini M, Indulti F, Spagnoli A, Merli M, Vizzutti F, Schepis F (2024) Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis. J Hepatol 80:596&#x02013;602. 10.1016/j.jhep.2023.11.033<pub-id pub-id-type="pmid">38097113</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>K</given-names></name><name><surname>Carrion</surname><given-names>AF</given-names></name><name><surname>Salsamendi</surname><given-names>J</given-names></name><name><surname>Doshi</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>R</given-names></name><name><surname>Kably</surname><given-names>I</given-names></name></person-group><article-title>Endovascular management of refractory hepatic Encephalopathy complication of transjugular intrahepatic portosystemic shunt (TIPS): Comprehensive Review and Clinical Practice Algorithm</article-title><source>Cardiovasc Intervent Radiol</source><year>2016</year><volume>39</volume><fpage>170</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/s00270-015-1197-x</pub-id><pub-id pub-id-type="pmid">26285910</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Pereira K, Carrion AF, Salsamendi J, Doshi M, Baker R, Kably I (2016) Endovascular management of refractory hepatic Encephalopathy complication of Transjugular Intrahepatic Portosystemic Shunt (TIPS): Comprehensive Review and Clinical Practice Algorithm. Cardiovasc Intervent Radiol 39:170&#x02013;182. 10.1007/s00270-015-1197-x<pub-id pub-id-type="pmid">26285910</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Praktiknjo</surname><given-names>M</given-names></name><name><surname>Sim&#x000f3;n-Talero</surname><given-names>M</given-names></name><name><surname>R&#x000f6;mer</surname><given-names>J</given-names></name><name><surname>Roccarina</surname><given-names>D</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>J</given-names></name><name><surname>Lampichler</surname><given-names>K</given-names></name><name><surname>Baiges</surname><given-names>A</given-names></name><name><surname>Low</surname><given-names>G</given-names></name><name><surname>Llop</surname><given-names>E</given-names></name><name><surname>Maurer</surname><given-names>MH</given-names></name><name><surname>Zipprich</surname><given-names>A</given-names></name><name><surname>Triolo</surname><given-names>M</given-names></name><name><surname>Maleux</surname><given-names>G</given-names></name><name><surname>Fialla</surname><given-names>AD</given-names></name><name><surname>Dam</surname><given-names>C</given-names></name><name><surname>Vidal-Gonz&#x000e1;lez</surname><given-names>J</given-names></name><name><surname>Majumdar</surname><given-names>A</given-names></name><name><surname>Pic&#x000f3;n</surname><given-names>C</given-names></name><name><surname>Toth</surname><given-names>D</given-names></name><name><surname>Darnell</surname><given-names>A</given-names></name><name><surname>Abraldes</surname><given-names>JG</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>M</given-names></name><name><surname>Jansen</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Schierwagen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis</article-title><source>J Hepatol</source><year>2020</year><volume>72</volume><fpage>1140</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.12.021</pub-id><pub-id pub-id-type="pmid">31954206</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Praktiknjo M, Sim&#x000f3;n-Talero M, R&#x000f6;mer J, Roccarina D, Mart&#x000ed;nez J, Lampichler K, Baiges A, Low G, Llop E, Maurer MH, Zipprich A, Triolo M, Maleux G, Fialla AD, Dam C, Vidal-Gonz&#x000e1;lez J, Majumdar A, Pic&#x000f3;n C, Toth D, Darnell A, Abraldes JG, L&#x000f3;pez M, Jansen C, Chang J, Schierwagen R et al (2020) Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. J Hepatol 72:1140&#x02013;1150. 10.1016/j.jhep.2019.12.021<pub-id pub-id-type="pmid">31954206</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Reiberger</surname><given-names>T</given-names></name><name><surname>Ferlitsch</surname><given-names>A</given-names></name><name><surname>Payer</surname><given-names>BA</given-names></name><name><surname>Mandorfer</surname><given-names>M</given-names></name><name><surname>Heinisch</surname><given-names>BB</given-names></name><name><surname>Hayden</surname><given-names>H</given-names></name><name><surname>Lammert</surname><given-names>F</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name><name><surname>Peck-Radosavljevic</surname><given-names>M</given-names></name><name><surname>Vogelsang</surname><given-names>H</given-names></name></person-group><article-title>Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis</article-title><source>J Hepatol</source><year>2013</year><volume>58</volume><fpage>911</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.12.011</pub-id><pub-id pub-id-type="pmid">23262249</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H (2013) Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 58:911&#x02013;921. 10.1016/j.jhep.2012.12.011<pub-id pub-id-type="pmid">23262249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>CF</given-names></name><name><surname>Amodio</surname><given-names>P</given-names></name><name><surname>Bajaj</surname><given-names>JS</given-names></name><name><surname>Dhiman</surname><given-names>RK</given-names></name><name><surname>Montagnese</surname><given-names>S</given-names></name><name><surname>Taylor-Robinson</surname><given-names>SD</given-names></name><name><surname>Vilstrup</surname><given-names>H</given-names></name><name><surname>Jalan</surname><given-names>R</given-names></name></person-group><article-title>Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><fpage>1526</fpage><lpage>1547</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.07.013</pub-id><pub-id pub-id-type="pmid">33097308</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R (2020) Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol 73:1526&#x02013;1547. 10.1016/j.jhep.2020.07.013<pub-id pub-id-type="pmid">33097308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>P</given-names></name><name><surname>Heinzow</surname><given-names>H</given-names></name><name><surname>Trebicka</surname><given-names>J</given-names></name><name><surname>Wildgruber</surname><given-names>M</given-names></name></person-group><article-title>Shunt-Induced hepatic encephalopathy in TIPS: current approaches and Clinical challenges</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><fpage>3784</fpage><pub-id pub-id-type="doi">10.3390/jcm9113784</pub-id><pub-id pub-id-type="pmid">33238576</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Schindler P, Heinzow H, Trebicka J, Wildgruber M (2020) Shunt-Induced hepatic encephalopathy in TIPS: current approaches and Clinical challenges. J Clin Med 9:3784. 10.3390/jcm9113784<pub-id pub-id-type="pmid">33238576</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="book"><person-group person-group-type="author"><name><surname>Schomerus</surname><given-names>H</given-names></name><name><surname>Weissenborn</surname><given-names>K</given-names></name><name><surname>Hamster</surname><given-names>W</given-names></name><name><surname>R&#x000fc;ckert</surname><given-names>N</given-names></name><name><surname>Hecker</surname><given-names>H</given-names></name></person-group><source>PSE-syndrom-test. Psychodiagnostisches Verfahren Zur Quantitativen Erfassung Der (Minimalen) Portosystemischen Enzephalopathie</source><year>1999</year><publisher-loc>Frankfurt</publisher-loc><publisher-name>Swets Test Services</publisher-name></element-citation><mixed-citation id="mc-CR35" publication-type="book">Schomerus H, Weissenborn K, Hamster W, R&#x000fc;ckert N, Hecker H (1999) PSE-syndrom-test. Psychodiagnostisches Verfahren Zur Quantitativen Erfassung Der (Minimalen) Portosystemischen Enzephalopathie. Swets Test Services, Frankfurt</mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Senzolo</surname><given-names>M</given-names></name><name><surname>Zarantonello</surname><given-names>L</given-names></name><name><surname>Formentin</surname><given-names>C</given-names></name><name><surname>Orlando</surname><given-names>C</given-names></name><name><surname>Beltrame</surname><given-names>R</given-names></name><name><surname>Vuerich</surname><given-names>A</given-names></name><name><surname>Angeli</surname><given-names>P</given-names></name><name><surname>Burra</surname><given-names>P</given-names></name><name><surname>Montagnese</surname><given-names>S</given-names></name></person-group><article-title>Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy</article-title><source>Metab Brain Dis</source><year>2019</year><volume>34</volume><fpage>1803</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1007/s11011-019-00490-5</pub-id><pub-id pub-id-type="pmid">31506797</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Senzolo M, Zarantonello L, Formentin C, Orlando C, Beltrame R, Vuerich A, Angeli P, Burra P, Montagnese S (2019) Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy. Metab Brain Dis 34:1803&#x02013;1812. 10.1007/s11011-019-00490-5<pub-id pub-id-type="pmid">31506797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Shawcross</surname><given-names>DL</given-names></name><name><surname>Davies</surname><given-names>NA</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Jalan</surname><given-names>R</given-names></name></person-group><article-title>Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis</article-title><source>J Hepatol</source><year>2004</year><volume>40</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2003.10.016</pub-id><pub-id pub-id-type="pmid">14739095</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Shawcross DL, Davies NA, Williams R, Jalan R (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 40:247&#x02013;254. 10.1016/j.jhep.2003.10.016<pub-id pub-id-type="pmid">14739095</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Shawcross</surname><given-names>DL</given-names></name><name><surname>Wright</surname><given-names>G</given-names></name><name><surname>Damink</surname><given-names>O</given-names></name><name><surname>Jalan</surname><given-names>R</given-names></name></person-group><article-title>Role of ammonia and inflammation in minimal hepatic encephalopathy</article-title><source>Metab Brain Dis</source><year>2007</year><volume>22</volume><fpage>125</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1007/s11011-006-9042-1</pub-id><pub-id pub-id-type="pmid">17260161</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Shawcross DL, Wright G, Damink O, S.W.M., and, Jalan R (2007) Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 22:125&#x02013;138. 10.1007/s11011-006-9042-1<pub-id pub-id-type="pmid">17260161</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Shawcross</surname><given-names>DL</given-names></name><name><surname>Sharifi</surname><given-names>Y</given-names></name><name><surname>Canavan</surname><given-names>JB</given-names></name><name><surname>Yeoman</surname><given-names>AD</given-names></name><name><surname>Abeles</surname><given-names>RD</given-names></name><name><surname>Taylor</surname><given-names>NJ</given-names></name><name><surname>Auzinger</surname><given-names>G</given-names></name><name><surname>Bernal</surname><given-names>W</given-names></name><name><surname>Wendon</surname><given-names>JA</given-names></name></person-group><article-title>Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis</article-title><source>J Hepatol</source><year>2011</year><volume>54</volume><fpage>640</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.07.045</pub-id><pub-id pub-id-type="pmid">21163546</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA (2011) Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 54:640&#x02013;649. 10.1016/j.jhep.2010.07.045<pub-id pub-id-type="pmid">21163546</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><mixed-citation publication-type="other">Sim&#x000f3;n-Talero M, Roccarina D, Mart&#x000ed;nez J, Lampichler K, Baiges A, Low G, Llop E, Praktiknjo M, Maurer MH, Zipprich A, Triolo M, Vangrinsven G, Garcia-Martinez R, Dam A, Majumdar A, Pic&#x000f3;n C, Toth D, Darnell A, Abraldes JG, Lopez M, Kukuk G, Krag A, Ba&#x000f1;ares R, Laleman W, La Mura V et al (2018) Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology 154:1694&#x02013;1705.e4. 10.1053/j.gastro.2018.01.028</mixed-citation></ref><ref id="CR41"><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Steib</surname><given-names>CJ</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Mayerle</surname><given-names>J</given-names></name><name><surname>Ricke</surname><given-names>J</given-names></name><name><surname>Gerbes</surname><given-names>AL</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Zipprich</surname><given-names>A</given-names></name><name><surname>Trebicka</surname><given-names>J</given-names></name></person-group><article-title>Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals</article-title><source>Eur J Gastroenterol Hepatol</source><year>2020</year><volume>32</volume><fpage>1179</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000001628</pub-id><pub-id pub-id-type="pmid">31851085</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Steib CJ, Li H, Zhang J, Mayerle J, Ricke J, Gerbes AL, Meyer C, Zipprich A, Trebicka J (2020) Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals. Eur J Gastroenterol Hepatol 32:1179&#x02013;1185. 10.1097/MEG.0000000000001628<pub-id pub-id-type="pmid">31851085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsien</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>McCullough</surname><given-names>A</given-names></name><name><surname>Dasarathy</surname><given-names>S</given-names></name></person-group><article-title>Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent</article-title><source>Eur J Gastroenterol Hepatol</source><year>2013</year><volume>25</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1097/MEG.0b013e328359a759</pub-id><pub-id pub-id-type="pmid">23011041</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Tsien C, Shah S, McCullough A, Dasarathy S (2013) Reversal of Sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol 25:85&#x02013;93. 10.1097/MEG.0b013e328359a759<pub-id pub-id-type="pmid">23011041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><mixed-citation publication-type="other">Weissenborn K (2015) Diagnosis of minimal hepatic encephalopathy. J Clin Experimental Hepatol 5S54&#x02013;S59. 10.1016/j.jceh.2014.06.005</mixed-citation></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Weissenborn</surname><given-names>K</given-names></name></person-group><article-title>Hepatic encephalopathy: definition, clinical grading and diagnostic principles</article-title><source>Drugs</source><year>2019</year><volume>79</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s40265-018-1018-z</pub-id><pub-id pub-id-type="pmid">30706420</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Weissenborn K (2019) Hepatic encephalopathy: definition, clinical Grading and Diagnostic principles. Drugs 79:5&#x02013;9. 10.1007/s40265-018-1018-z<pub-id pub-id-type="pmid">30706420</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>